Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000986178
Ethics application status
Approved
Date submitted
28/05/2019
Date registered
11/07/2019
Date last updated
15/10/2021
Date data sharing statement initially provided
11/07/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
The Assessment of Fluoxetine in Stroke Recovery Imaging and Blood Biomarkers Sub - Study AFFINITY BM
Scientific title
The Assessment of Fluoxetine in Stroke Recovery Imaging and Blood Biomarkers Sub - Study AFFINITY BM
Secondary ID [1] 296896 0
nil known
Universal Trial Number (UTN)
Nil Known
Trial acronym
Nil
Linked study record
Sub Study of the The Assessment of Fluoxetine in Stroke Recovery [ The AFFINITY Trial ACTRN 12611000774921]

Health condition
Health condition(s) or problem(s) studied:
stroke 312121 0
Condition category
Condition code
Neurological 310674 310674 0 0
Other neurological disorders
Stroke 311636 311636 0 0
Ischaemic
Stroke 311637 311637 0 0
Haemorrhagic

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
1. Fluoxetine or placebo (double-blind) as the study drug under investigation in the main AFFINITY trial (ACTRN: 12611000774921)

2. Blood sample for biochemical and DNA analysis to be collected at Baseline/Randomisation if possible; and if not at any of the other main AFFINITY trial follow up assessment points [Day 28, Day 90, Day 180, Day 365 Visits]

3. MRI brain scan at Baseline/Randomisation and at the Day 180 Follow Up Assessment Visit for the main AFFINITY Trial.

4. All Main trial follow up continues as per protocol.
Intervention code [1] 321964 0
Diagnosis / Prognosis
Comparator / control treatment
none
Control group
Uncontrolled

Outcomes
Primary outcome [1] 319519 0
Activation in the ipsilesional primary motor and medial-premotor cortices [composite primary outcomes] as measured by task-related functional magnetic resonance imaging (MRI) at 6 months.
Timepoint [1] 319519 0
6 months
Primary outcome [2] 319520 0
Genetic blood biomarkers of functional neurological recovery, as an exploratory outcome.
Markers of interest to be analysed by DNA analysis of the blood include the Apo Ee4 polymorphism, Val66met brain-derived neurotrophic factor (BDNF )polymorphism, and R0 mitochondrial DNA haplotype.
Timepoint [2] 319520 0
6 months
Primary outcome [3] 320515 0
Biochemical biomarkers of functional neurological recovery, as an exploratory outcome.

Markers of interest to be analysed by haematological and biochemical analysis of of the blood include the White cell count, Glucose, C-reactive protein, Interleukin-6, Fibrinogen,
N-terminal pro-B-type natriuretic peptide, Heart-type fatty-acid-binding protein, Soluble TNF a receptor-1, and von Willebrand factor
Timepoint [3] 320515 0
6 months
Secondary outcome [1] 368563 0
Interhemispheric connectivity of sensorimotor cortices on fMRI
Timepoint [1] 368563 0
6 months
Secondary outcome [2] 371666 0
Functional connectivity of depression-related brain networks on fMRI
Timepoint [2] 371666 0
6 months
Secondary outcome [3] 371667 0
Thickness of cortical grey matter in the ipsilesional primary motor cortex on fMRI
Timepoint [3] 371667 0
6 Months
Secondary outcome [4] 371668 0
Volume of the qualifying stroke lesion on MRI
Timepoint [4] 371668 0
6 Months
Secondary outcome [5] 371669 0
White matter microstructural integrity on fMRI
Timepoint [5] 371669 0
6 Months
Secondary outcome [6] 371885 0
Thickness of cortical grey matter in the ipsilesional amygdala on fMRI
Timepoint [6] 371885 0
6 months
Secondary outcome [7] 371886 0
Thickness of the cortical grey matter in the ipsilesional hippocampus as assessed by MRI scan
Timepoint [7] 371886 0
6 months
Secondary outcome [8] 372313 0
Connectivity of white matter tracts on fMRI
Timepoint [8] 372313 0
6 months

Eligibility
Key inclusion criteria
Participants may partake of either one or both of the sub studies

Inclusion criteria: Blood Biomarkers sub study:
Participants randomised and participating in the AFFINITY Trial

Inclusion criteria: MRI neuroimaging sub study:
Participants randomised and participating in the AFFINITY Trial
Brain imaging consistent with an ischaemic stroke of either hemisphere
Brain imaging conducted within 21 days of qualifying stroke event
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria: MRI neuroimaging sub study:
Brain imaging consistent with haemorrhagic (intracerebral and / or subarachnoid) stroke
Contra-indication to having a MRI e.g. implanted pacemaker or severe claustrophobia (these people can still participate in the blood biomarker sub-study)
Unable to undergo follow up MRI at six months

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
Statistical methods
We will analyse and store the data using reliable statistical software (STATA). Baseline data will be compared using descriptive statistics, Student t tests for normally distributed continuous variables, Mann-Whitney test for skewed variables and Pearson’s chi-square statistic for categorical variables.
MRI analyses
Regional grey matter volume differences will be assessed though voxel-based morphometry (VBM) using SPM12. Significant effects will be assessed using a family-wise error (FWE) threshold of p < 0.05, corrected for multiple comparisons. Age, gender, stroke lesion size and intracranial volume will be included as nuisance covariates in the models. Functional MRI data will be analysed with SPM12 utilising appropriate toolkits and we will use Stroketool software (http://www.digitalimagesolutions.de/) to assess lesion size.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
18/03/2016
Date of last participant enrolment
Anticipated
31/12/2020
Actual
5/06/2020
Date of last data collection
Anticipated
31/12/2020
Actual
5/06/2020
Sample size
Target
1600
Accrual to date
Final
241
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 13464 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [2] 13465 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [3] 13566 0
Redcliffe Hospital - Redcliffe
Recruitment postcode(s) [1] 26073 0
6009 - Nedlands
Recruitment postcode(s) [2] 26074 0
6150 - Murdoch
Recruitment postcode(s) [3] 26212 0
4020 - Redcliffe
Recruitment outside Australia
Country [1] 21363 0
Viet Nam
State/province [1] 21363 0
Ho Chi Minh City, Hanoi and Thanh Hoa Province

Funding & Sponsors
Funding source category [1] 301467 0
Government body
Name [1] 301467 0
National Health and Medical Research Council - Program Grant
Country [1] 301467 0
Australia
Primary sponsor type
Hospital
Name
Sir Charles Gairdner Hospital
Address
Hospital Avenue
Nedlands
Perth, WA
6009
Country
Australia
Secondary sponsor category [1] 302947 0
None
Name [1] 302947 0
Address [1] 302947 0
Country [1] 302947 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302206 0
Royal Perth Hospital Ethics Committee
Ethics committee address [1] 302206 0
Ethics committee country [1] 302206 0
Australia
Date submitted for ethics approval [1] 302206 0
01/01/2016
Approval date [1] 302206 0
05/03/2019
Ethics approval number [1] 302206 0
Ethics committee name [2] 303090 0
WSLHD Human Research Ethics Committee
Ethics committee address [2] 303090 0
Ethics committee country [2] 303090 0
Australia
Date submitted for ethics approval [2] 303090 0
31/05/2016
Approval date [2] 303090 0
07/09/2016
Ethics approval number [2] 303090 0
REC/16/WMEAD/127

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 89462 0
Prof Graeme Hankey
Address 89462 0
Harry Perkins Institute of Medical Research
2nd Floor, QQ Block
Sir Charles Gairdner Hospital
6 Verdun Street
Nedlands, Western Australia 6009
Country 89462 0
Australia
Phone 89462 0
+61 8 6151 1061
Fax 89462 0
Email 89462 0
graeme.hankey@uwa.edu.au
Contact person for public queries
Name 89463 0
Anne Claxton
Address 89463 0
Harry Perkins Institute of Medical Research
2nd Floor, QQ Block
Sir Charles Gairdner Hospital
6 Verdun Street
Nedlands, Western Australia 6009
Country 89463 0
Australia
Phone 89463 0
+61 86151 1061
Fax 89463 0
Email 89463 0
anne.claxton@health.wa.gov.au
Contact person for scientific queries
Name 89464 0
Graeme Hankey
Address 89464 0
Harry Perkins Institute of Medical Research
2nd Floor, QQ Block
Sir Charles Gairdner Hospital
6 Verdun Street
Nedlands, Western Australia 6009
Country 89464 0
Australia
Phone 89464 0
+61 86151 1061
Fax 89464 0
Email 89464 0
graeme.hankey@uwa.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.